FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:76-77 July 6, 2006 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cunningham, D. PubMed Citation

Gastric and gastroesophageal adenocarcinomas are important health problems. A 2005 analysis¹ of the worldwide incidence of and mortality from cancer showed that 934,000 cases of gastric cancer occurred in 2002 and that 700,000 patients die annually of this disease. The management of gastric cancer, like the management of most gastrointestinal cancers, is based on surgical resection of the primary tumor. When the cancer is localized to the stomach and is minimally invasive,^2,3 surgical cure is possible in up to 90 percent of cases. However, the detection of early gastric cancer is unusual in Western countries. More commonly, resectable gastric cancer . . . [Full Text of this Article]

Source Information

From St. Vincent's Comprehensive Cancer Center, New York, and Aptium Oncology, Los Angeles.

This article has been cited by other articles:

• Lieto, E., Ferraraccio, F., Orditura, M., Castellano, P., La Mura, A., Pinto, M., Zamboli, A., DeVita, F., Galizia, G. (2008). Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. Ann. Surg. Oncol. 15: 69-79 [Abstract] [Full Text]  
• de Maat, M. F.G., van de Velde, C. J.H., Umetani, N., de Heer, P., Putter, H., van Hoesel, A. Q., Meijer, G. A., van Grieken, N. C., Kuppen, P. J.K., Bilchik, A. J., Tollenaar, R. A.E.M., Hoon, D. S.B. (2007). Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. JCO 25: 4887-4894 [Abstract] [Full Text]  
• Briasoulis, E., Fatouros, M., Roukos, D. H. (2007). Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use?. Ann. Surg. Oncol. 14: 2691-2695 [Full Text]  
• Lutz, M. P., Wilke, H., Wagener, D.J. T., Vanhoefer, U., Jeziorski, K., Hegewisch-Becker, S., Balleisen, L., Joossens, E., Jansen, R. L., Debois, M., Bethe, U., Praet, M., Wils, J., Van Cutsem, E. (2007). Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. JCO 25: 2580-2585 [Abstract] [Full Text]